Have a feature idea you'd love to see implemented?
Let us know!
SER Serina Therapeutics Inc.
Price (delayed)
$4.9
Market cap
$43.57M
P/E Ratio
0.48
Dividend/share
N/A
EPS
$10.24
Enterprise value
$51.8M
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic
Highlights
The P/E is 78% lower than the last 4 quarters average of 2.2
The equity is up by 50% year-on-year and by 16% since the previous quarter
The quick ratio has dropped by 51% since the previous quarter but it has surged by 50% year-on-year
The net income rose by 48% year-on-year but it has declined by 2.4% since the previous quarter
Key stats
What are the main financial stats of SER
Market
Valuations
Earnings
Shares outstanding
8.89M
Market cap
$43.57M
Enterprise value
$51.8M
Price to earnings (P/E)
0.48
Price to book (P/B)
N/A
Price to sales (P/S)
13.82
EV/EBIT
5.3
EV/EBITDA
5.05
EV/Sales
16.51
Revenue
$3.14M
EBIT
$9.78M
EBITDA
$10.26M
Free cash flow
-$9.8M
Per share
Balance sheet
Liquidity
EPS
$10.24
Free cash flow per share
-$1.11
Book value per share
-$1.55
Revenue per share
$0.35
TBVPS
$0.78
Total assets
$7.44M
Total liabilities
$21.26M
Debt
$11.47M
Equity
-$13.77M
Working capital
-$8.09M
Debt to equity
-0.83
Current ratio
0.4
Quick ratio
0.24
Net debt/EBITDA
0.8
Margins
Efficiency
Dividend
EBITDA margin
326.9%
Gross margin
101.2%
Net margin
439.6%
Operating margin
-262.5%
Return on assets
145.3%
Return on equity
N/A
Return on invested capital
583.4%
Return on capital employed
N/A
Return on sales
311.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SER stock price
How has the Serina Therapeutics stock price performed over time
Intraday
-6.84%
1 week
-2%
1 month
-34.75%
1 year
-66.02%
YTD
-63.81%
QTD
-26.76%
Financial performance
How have Serina Therapeutics's revenue and profit performed over time
Revenue
$3.14M
Gross profit
$3.18M
Operating income
-$8.24M
Net income
$13.79M
Gross margin
101.2%
Net margin
439.6%
The company's operating margin has shrunk by 89% QoQ
The company's operating income has shrunk by 88% QoQ
The company's net margin has shrunk by 70% YoY
The net income rose by 48% year-on-year but it has declined by 2.4% since the previous quarter
Growth
What is Serina Therapeutics's growth rate over time
Valuation
What is Serina Therapeutics stock price valuation
P/E
0.48
P/B
N/A
P/S
13.82
EV/EBIT
5.3
EV/EBITDA
5.05
EV/Sales
16.51
The P/E is 78% lower than the last 4 quarters average of 2.2
The company's EPS rose by 33% YoY but it fell by 6% QoQ
The equity is up by 50% year-on-year and by 16% since the previous quarter
The price to sales (P/S) is 89% lower than the 5-year quarterly average of 128.4 and 17% lower than the last 4 quarters average of 16.7
Efficiency
How efficient is Serina Therapeutics business performance
The ROIC has soared by 117% QoQ
The company's return on sales has shrunk by 73% YoY and by 3.7% QoQ
Serina Therapeutics's ROA has increased by 48% YoY and by 10% from the previous quarter
Dividends
What is SER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SER.
Financial health
How did Serina Therapeutics financials performed over time
Serina Therapeutics's total assets is 65% lower than its total liabilities
The quick ratio has dropped by 51% since the previous quarter but it has surged by 50% year-on-year
The company's current ratio fell by 44% QoQ but it rose by 11% YoY
The company's debt is 183% higher than its equity
The equity is up by 50% year-on-year and by 16% since the previous quarter
The debt to equity has declined by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.